source
- Apnimed upsizes IPO to $192 million to fund launch of oral sleep‑apnea drugApnimed, a Massachusetts‑based biotech, announced an upsized initial public offering that now includes 12 million shares priced at $16 each, generating $192 million in gross proceeds. This amount e…
- Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 failA phase 3 trial of Novo Nordisk’s ziltivekimab has missed its primary endpoint, denting the prospects of a molecule analysts tipped to generate blockbuster sales and diversify the company’s portfol…Fierce Biotech · 5h ago↗ source